Terapia celular
Terapia celular, células madre y tejidos
Coordinador/a del grupo
-
Cristina Eguizabal Argaiz
Coordinador del grupo
cristina.eguizabalargaiz@bio-bizkaia.eus
CV resumen
Miembros del grupo
Publicaciones del grupo
Sanchez Guijo F, Avendano Sola C, Badimon L, Bueren JA, Canals JM, Delgadillo J, et al. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV). Bone Marrow Transplant. 2023; 58(6): 727-728. DOI:10.1038/s41409-023-01962-0.
Demarta Gatsi C, Andenmatten N, Jimenez Diaz M, Gobeau N, Cherkaoui Rabti MH, Fuchs A, et al. Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model. Antimicrob Agents Chemother. 2023; 67(6). DOI:10.1128/aac.01574-22.
Herrera L, Martin Inaraja M, Bengoetxea A, Vendrell A, Perez Fernandez S, Eguizabal C, et al. Natural killer cell subsets in endometrial fluid: a pilot study of their association with the endometrial cycle and reproductive parameters. J Assist Reprod Genet. 2023; 40(9): 2241-2250. DOI:10.1007/s10815-023-02862-4.
Martin Iglesias S, Herrera L, Santos S, Vesga MA, Eguizabal C, Lanceros Mendez S, et al. Analysis of the impact of handling and culture on the expansion and functionality of NK cells. Front Immunol. 2023; 14. DOI:10.3389/fimmu.2023.1225549.
Czukiewska SM, Fan X, Mulder AA, Van Der Helm T, Hillenius S, Van Der Meeren L, et al. Cell-cell interactions during the formation of primordial follicles in humans. Life Sci Alliance. 2023; 6(11). DOI:10.26508/lsa.202301926.
Gonzaga A, Andreu E, Hernandez Blasco LM, Meseguer R, Al Sanz K, Soria Juan B, et al. Rationale for combined therapies in severe-to-critical COVID-19 patients. Front Immunol. 2023; 14: 1232472-1232472. DOI:10.3389/fimmu.2023.1232472.
Ferreras C, Hernandez Blanco C, Martin Quiros A, Al Sanz K, Mora Rillo M, Ibanez F, et al. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210). Cytotherapy. 2023. DOI:10.1016/j.jcyt.2023.10.002.
Herrera L, Martin Inaraja M, Santos S, Ingles Ferrandiz M, Azkarate A, Perez Vaquero MA, et al. Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy. Immunology. 2022; 165(2): 234-249. DOI:10.1111/imm.13432.
Romayor I, Luque Garcia Vaquero M, Marquez J, Arteta B, Barcelo R, Benedicto A. Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer. Breast J. 2022; 2022. DOI:10.1155/2022/5169405.
Romayor I, Herrera L, Buron M, Martin Inaraja M, Prieto L, Etxaniz J, et al. A Comparative Study of Cell Culture Conditions during Conversion from Primed to Naive Human Pluripotent Stem Cells. Biomedicines. 2022; 10(6). DOI:10.3390/biomedicines10061358.
Alvarez Palomo B, Veiga A, Raya A, Codinach M, Torrents S, Verdugo LP, et al. Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells. Stem Cell Res Ther. 2022; 13(1). DOI:10.1186/s13287-022-02961-6.
Martin Inaraja M, Alonso S, Rodriguez C, Santos S, Iglesias M, Prieto B, et al. DNA-FISH analysis in testicular tissue cells of prepuberal patients with Klinefelter Syndrome. Hum Reprod. 2022; 37
Ferreras C, Pascual Miguel B, Mestre Duran C, Navarro Zapata A, Clares Villa L, Martin Cortazar C et al. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy. Front Cell Dev Biol. 2021; 9: 620730-620730. DOI:10.3389/fcell.2021.620730.
Munoz Culla M, Roncancio Clavijo A, Martinez B, Gorostidi Aicua M, Pineiro L, Azkune A et al. O group is a protective factor for COVID19 in Basque population. PLoS One. 2021; 16(4): 249494-249494. DOI:10.1371/journal.pone.0249494.
Alvarez Palomo B, Garcia Martinez I, Gayoso J, Raya A, Veiga A, Abad ML et al. Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells. Stem Cell Res Ther. 2021; 12(1): 233-233. DOI:10.1186/s13287-021-02301-0.
Eguizabal C, Herrera L, Ingles Ferrandiz M, Belmonte JCI. Correction to: Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing. Stem Cell Res Ther. 2021; 12(1): 250-250. DOI:10.1186/s13287-021-02281-1.
Garcia Hevia L, Saramiforoshani M, MONGE RUIZ J, Iturrioz Rodriguez N, Padin Gonzalez E, Gonzalez F et al. The unpredictable carbon nanotube biocorona and a functionalization method to prevent protein biofouling. J Nanobiotechnol. 2021; 19(1). DOI:10.1186/s12951-021-00872-x.
Perez Martinez A, Ferreras C, Mora Rillo M, Guerra P, Pascual Miguel B, Mesrtre Duran C et al. A Phase I Dose-Escalation Single Center Study To Evaluate The Safety Of Allogenic Memory T Cells Containing SARS-COV-2 Specific Lymphocytes As Adoptive Therapy in COVID19. Bone Marrow Transplant. 2021; 56(SUPPL 1): 49-50
Germain M, Gregoire Y, Custer BS, Goldman M, Bravo M, Kamel H et al. An international comparison of HIV prevalence and incidence in blood donors and general population: a BEST Collaborative study. Vox Sang. 2021; 116(10): 1084-1093. DOI:10.1111/vox.13107.
Martin Inaraja M, Ferreira M, Taelman J, Eguizabal C, Lopes SMCD. Improving In Vitro Culture of Human Male Fetal Germ Cells. Cells. 2021; 10(8). DOI:10.3390/cells10082033.
Delgado E, Fernandez Garcia A, Perez Losada M, Moreno Lorenzo M, Fernandez Miranda I, Benito S et al. Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America (vol 11, 11442, 2021). Sci Rep. 2021; 11(1). DOI:10.1038/s41598-021-95679-z.
Sainz E, Zabana Y, Miguel I, Fernandez Clotet A, Beltran B, Nunez L et al. Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). Aliment Pharmacol Ther. 2021; 54(8): 1041-1051. DOI:10.1111/apt.16547.
Fan X, Moustakas I, Torrens Juaneda V, Lei Q, Hamer G, Louwe LA et al. Transcriptional progression during meiotic prophase I reveals sex-specific features and X chromosome dynamics in human fetal female germline. PLoS Genet. 2021; 17(9): 1009773-1009773. DOI:10.1371/journal.pgen.1009773.
Garcia I, Guerra Garcia P, Ferreras C, Borobia AM, Carcas AJ, Queiruga Parada J et al. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. Trials. 2021; 22(1). DOI:10.1186/s13063-021-05625-7.
Perez Martinez A, Mora Rillo M, Ferreras C, Guerra Garcia P, Pascual Miguel B, Mestre Duran C et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). Eclinicalmedicine. 2021; 39. DOI:10.1016/j.eclinm.2021.101086.
Bizkarguenaga M, Bruzzone C, Gil Redondo R, SanJuan I, Martin Ruiz I, Barriales D et al. Uneven metabolic and lipidomic profiles in recovered COVID-19 patients as investigated by plasma NMR metabolomics. NMR Biomed. 2021; 35(2): 4637-4637. DOI:10.1002/nbm.4637.
Herrera L, Santos S, Vesga MA, Carrascosa T, Garcia Ruiz JC, Perez Martinez A et al. The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. Cancers (Basel). 2021; 13(21). DOI:10.3390/cancers13215418.
Martin M, Ferreira M, Taelman J, Eguizabal C, Lopes SMCDS. Novel culture conditions for the improvement of the in vitro expansion of human male fetal germ cells. Hum Reprod. 2021; 36: 502-503
Perez Martinez A, Ferreras C, Mora Rillo M, Guerra P, Pascual Miguel B, Mestre Duran C et al. A PHASE I/II DOSE-ESCALATION SINGLE CENTER STUDY TO EVALUATE THE SAFETY OF INFUSION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND /OR LYMPHOPENIA (RELEASE). Cytotherapy. 2021; 23(5): 29-29
Antonio PM, Cristina FP, Alejandro MQ, Karima AK, Pilar GG, Barbara PM et al. PRELIMINARY RESULTS OF THE PHASE I/II RELEASE CLINICAL TRIAL WITH ADOPTIVE CELL THERAPY WITH MEMORY T-LYMPHOCYTES FOR PATIENTS WITH MODERATE/SEVERE COVID19 DISEASE. Haematologica. 2021; 106(10): 128-128
Romayor I, Ferrandiz MI, Inaraja MM, Herrera L, Santos S, Vesga MA et al. Modelling APDS2 syndrome for future gene and cell therapy. Eur J Immunol. 2021; 51: 357-357
Londero D, Monge J, Hellberg A. A multi-centre study on the performance of the molecular genotyping platform ID RHD XT for resolving serological weak RhD phenotype in routine clinical practice. Vox Sang. 2020; 115(3): 241-248. DOI:10.1111/vox.12886.
Gorria C, Labata G, Lezaun M, López FJ, Pérez Aliaga AI, Pérez Vaquero MÁ. Impact of implementing pathogen reduction technologies for platelets on reducing outdates. Vox Sang. 2020; 115(2): 167-173. DOI:10.1111/vox.12860.
Myriam M, Armendariz E, Herrera L, Rodriguez C, Roig N, Garcia Quevedo L, et al. Future stem cell therapies in fertility preservation of prepuberal children with cancer or genetic syndromes. Improvements in the characterization of human Spermatogonial Stem Cells. Hum Reprod. 2020; 35: 1505-1506
Herrera L, Juan M, Eguizabal C. Purification, Culture, and CD19-CAR Lentiviral Transduction of Adult and Umbilical Cord Blood NK Cells. Current Protocols in Immunology. 2020; 131(1): 108-108. DOI:10.1002/cpim.108.
Villalba R, Santos S, Martinez MJ, Diaz M, Pevida M, Cemborain A, et al. Analysis of impact on tissue activity during COVID-19 outbreak: a survey of 8 banks in Spain. Cell Tissue Banking. 2020; 21(4): 557-562. DOI:10.1007/s10561-020-09853-0.
Eguizabal C, Herrera L, Ingles Ferrandiz M, Izpisua Belmonte JC. Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing. Stem Cell Res Ther. 2020; 11(1): 453-453. DOI:10.1186/s13287-020-01964-5.
Mikkelsen C, Mori G, van Walraven SM, Castren J, Zahra S, MacLennan S, et al. Putting the spotlight on donation-related risks and donor safety - are we succeeding in protecting donors?. Vox Sang. 2020; 116(3): 313-323. DOI:10.1111/vox.13014.
Mikkelsen C, Mori G, van Walraven SM, Castren J, Zahra S, MacLennan S, et al. How donor selection criteria can be evaluated with limited scientific evidence: lessons learned from the TRANSPOSE project. Vox Sang. 2020; 116(3): 342-350. DOI:10.1111/vox.13028.
Ingles Ferrandiz M, Martin Inaraja M, Herrera L, Villaverde M, Santos S, Vesga MA, et al. Generation, establishment and characterization of a pluripotent stem cell line (CVTTHi001-A) from primary fibroblasts isolated from a patient with activated PI3 kinase delta syndrome (APDS2). Stem Cell Res. 2020; 49: 102082-102082. DOI:10.1016/j.scr.2020.102082.
Matteocci A, Monge Ruiz J, Stef M, Apraiz I, Herrera Val L, Mancuso T, et al. Two new RHD alleles with deletions spanning multiple exons. Transfusion. 2020; 61(3): 682-686. DOI:10.1111/trf.16199.
Herrera L, Santos S, Angel Vesga M, Anguita J, Martin Ruiz I, Carrascosa T, et al. Adult Peripheral Blood and Umbilical Cord Blood NK Cells Are Good Sources for Effective Car Therapy Against CD19 Positive Leukemic Cells. Bone Marrow Transplant. 2020; 55(SUPPL 1): 263-264
Domanovic D, Ushiro Lumb I, Compernolle V, Brusin S, Funk M, Gallian P, et al. Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting. Blood Transfus. 2019; 17(6): 433-448. DOI:10.2450/2019.0288-19.
Herrera L, Santos S, Vesga MA, Anguita J, Martin Ruiz I, Carrascosa T, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against cd19 positive leukemic cells. Hum Gene Ther. 2019; 30(11): 59-59
Herrera L, Santos S, Vesga MA, Anguita J, Martin Ruiz I, Carrascosa T, et al. ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS. Hum Gene Ther. 2019; 30(12): 18-18
Herrera L, Santos S, Vesga MA, Anguita J, Martin Ruiz I, Carrascosa T, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep. 2019; 9(1): 18729-18729. DOI:10.1038/s41598-019-55239-y.
Sánchez Ibáñez J, Vilarrodona Serrat A, Seoane Pillado T, Rodriguez Aierbe C, Villalba Montoro R, Calvo Benito J, et al. Evaluation of occult hepatitis B infection in tissue donors: a multicenter analysis in Spain. Cell Tissue Banking. 2019; 20(4): 513-526. DOI:10.1007/s10561-019-09784-5.
Tesis del grupo
Autor/a: Lara Herrera Del Val. Título: Arming NK cells with chimeric antigen receptors (CARs) for treatment of refractory and/or relapsed hematological cancers: preclinical study to determine the best cell source. Directores/as: Dr. Jon Andoni Arluzea De Jauregizar, Dra. Cristina Eguizabal Argaiz. URL: http://hdl.handle.net/10810/49895.